prikaz prve stranice dokumenta The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
  Preuzmi
PDF 960.39 KB
Znanstveni rad - Izvorni znanstveni rad
The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
Urologic Oncology, 37 (2019), 9; 578.e1-578.e10. https://doi.org/10.1016/j.urolonc.2019.03.007
Knezović Florijan, Marijana; Ozretić, Petar; Bujak, Maro; Pezzè, Laura; Ciribilli, Yari; Kaštelan, Željko; Slade, Neda; Hudolin, Tvrtko

Citirajte ovaj rad

Knezović Florijan, M., Ozretić, P., Bujak, M., Pezzè, L., Ciribilli, Y., Kaštelan, Ž. ... Hudolin, T. (2019). The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urologic Oncology, 37. (9), 578.e1-578.e10. doi: 10.1016/j.urolonc.2019.03.007

Knezović Florijan, Marijana, et al. "The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis." Urologic Oncology, vol. 37, br. 9, 2019, str. 578.e1-578.e10. https://doi.org/10.1016/j.urolonc.2019.03.007

Knezović Florijan, Marijana, Petar Ozretić, Maro Bujak, Laura Pezzè, Yari Ciribilli, Željko Kaštelan, Neda Slade i Tvrtko Hudolin. "The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis." Urologic Oncology 37, br. 9 (2019): 578.e1-578.e10. https://doi.org/10.1016/j.urolonc.2019.03.007

Knezović Florijan, M., et al. (2019) 'The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis', Urologic Oncology, 37(9), str. 578.e1-578.e10. doi: 10.1016/j.urolonc.2019.03.007

Knezović Florijan M, Ozretić P, Bujak M, Pezzè L, Ciribilli Y, Kaštelan Ž, i sur.. The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urologic Oncology [Internet]. 09.2019. [pristupljeno 13.10.2024.];37(9):578.e1-578.e10. doi: 10.1016/j.urolonc.2019.03.007

M. Knezović Florijan, et al., "The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis", Urologic Oncology, vol. 37, br. 9, str. 578.e1-578.e10, Rujan 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:861680. [Citirano: 13.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:861680
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis
AutorMarijana Knezović Florijan
AutorPetar Ozretić
AutorMaro Bujak
AutorLaura Pezzè
AutorYari Ciribilli
AutorŽeljko Kaštelan
AutorNeda Slade
AutorTvrtko Hudolin
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Objectives: To analyze p53 mutations and gene expression of p53, ∆40p53, and ∆133p53 isoforms in renal cell cancer (RCC) tissues and normal adjacent tissue (NAT) and to associate them to clinical features and outcome. ----- Patients and methods: Forty-one randomly selected patients, with primary, previously untreated RCC, with complete clinicopathohistological data were analyzed. NAT samples were available for 37 cases. Expression of p53, ∆40p53 and ∆133p53 was determined using RT-qPCR. A functional yeast-based assay was performed to analyze p53 mutations. ----- Results: More than half (56.1%) of patients harbored functional p53 mutations, and they were significantly younger than those with wild type (WT) p53 (P = 0.032). Expression of p53, ∆40p53, and ∆133p53 was upregulated in mutant (MT) p53 RCC compared to WT p53 RCC tissues. However, there was no difference in expression of these isoforms between MT p53 RCC tissues and NAT. Expression of ∆133p53 was significantly downregulated in WT p53 tissues compared to NAT (P = 0.006). Patients that harbored functional p53 mutation had better overall survival (hazard ratio 4.32, 95% confidence interval 1.46-18.82, P = 0.006). Multivariate analysis demonstrated that tumor stage and p53 mutation might be used as independent prognostic marker for overall survival in RCC patients. ----- Conclusions: Our findings support the specific events in the carcinogenesis of RCC. p53 isoforms can be differentially expressed depending on p53 mutational status.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaUrologic Oncology
Brojčani podacivol. 37, br. 9, str. 578.e1-578.e10
p-ISSN1078-1439
DOIhttps://doi.org/10.1016/j.urolonc.2019.03.007
URN:NBNurn:nbn:hr:105:861680
Datum objave publikacije2019-09
URL dokumentahttp://doi.org/10.1016/j.urolonc.2019.03.007
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:41:57